V8 Peptides — Engineered Performance
Research Library
Selank Anxiolytic Peptide Research: Models and Readouts
SelankPreclinical

Selank Anxiolytic Peptide Research: Models and Readouts

V8 Peptides Research TeamUpdated

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

Quick answer

What does Selank anxiolytic peptide research actually consist of? It is a set of rodent behavioral paradigms (open field, elevated plus-maze, withdrawal scoring) paired with molecular readouts such as enkephalin-degrading enzyme activity, GABAergic gene expression and receptor-binding assays. Published work reports behavioral effects in some strains and not others, and the mechanism is described at the pathway level rather than as one confirmed receptor. This article explains how those models are built, what each readout can and cannot show, and how to document an experiment so results are interpretable. Selank is supplied by V8 Peptides as a 10 mg lyophilized vial, for laboratory research use only.

"Anxiolytic" is a label that comes from the models, not from the molecule's chemistry. Selank, the heptapeptide Thr-Lys-Pro-Arg-Pro-Gly-Pro, earned that label in animal paradigms in which a reduction in avoidance or an increase in exploration is scored as an anxiety-related change. Anyone designing a bench study around it needs to know how those paradigms work, why strain matters, and which molecular readouts the literature has attached to them. The Selank research guide covers structure and history; this piece is about the behavioral and mechanistic models specifically. It is written for laboratory research use only.

What the anxiolytic label means in preclinical work

In preclinical pharmacology, an anxiolytic-like effect is an operational finding: an animal exposed to a compound spends more time in an exposed or novel space, or shows fewer defensive behaviors, than a vehicle-exposed control. It says nothing by itself about receptors. The elevated plus-maze is the standard example. Pellow and colleagues validated the open-versus-closed arm design in rats, showing that rats entered open arms less than closed arms, showed more anxiety-related behaviors and had higher plasma corticosterone when confined to the open arms, and that anxiolytic and anxiogenic drugs moved the open-arm measures in opposite directions (reference 1).

Selank studies borrow that logic. Reports describe it in the open-field test, the elevated plus-maze and in a naloxone-precipitated morphine withdrawal model in rats, where a published Selank group showed lower composite withdrawal scores than the control group and a higher tactile sensitivity threshold (reference 2). Each model measures something slightly different, which is why the same compound can look active in one and inactive in another.

The peptide itself is simple to describe: seven residues, formula C33H57N11O9, supplied on the Selank product page as a lyophilized powder in a 10 mg vial with purity stated as ≥98% by HPLC. Its first four residues reproduce tuftsin, and a Pro-Gly-Pro tail was added to slow peptidase breakdown.

The behavioral models used with Selank

Four families of readout recur in the literature. The table summarizes what each captures and the main caution a reader should carry into the data.

ModelWhat is scoredReported with SelankMain caution
Open fieldLocomotion, rearing, center versus periphery timeAnxiolytic-like effect in BALB/c mice; none in C57Bl/6 mice (reference 3)Exploration and anxiety-related avoidance are confounded
Elevated plus-mazeOpen-arm entries and time as a fraction of totalEffect seen in BALB/c, not C57BL/6 mice, by both intranasal and intraperitoneal routes (reference 4)Report open-arm entries and time as a fraction of totals
Morphine withdrawal scoringComposite index of convulsions, ptosis, posture, sensitivity thresholdLower total index in a single-administration rat study (reference 2)Single-lab result; scoring is partly observer-dependent
Social stress paradigmsBehavior plus cytokine levels after repeated confrontationsCytokine readouts reported in rats under sensory-contact stress (reference 5)Cytokine panels vary by assay and timing

Two points stand out. First, strain dependence is not a footnote: the plus-maze comparison in BALB/c and C57BL/6 mice found effects only in the strain with lower baseline exploration and higher baseline anxiety, and the open-field study found the same split (references 3 and 4). A study run only in a low-anxiety strain could easily record "no effect" for reasons unrelated to the compound. Second, the abstracts report modest, specific effects, and the most careful reading is that Selank has been described as active under defined conditions, not universally.

Molecular readouts paired with the behavior

Because behavior cannot identify a mechanism, papers attach biochemical measurements. Three lines of work are most cited.

Enkephalin-degrading enzymes

Selank dose-dependently inhibited enzymatic hydrolysis of plasma enkephalin in an in vitro study, with a reported IC50 of 15 µM, and was described as more potent than the peptidase inhibitors bacitracin and puromycin in that assay (reference 6). A separate human-serum study reported IC50 values of 20 µM for Selank and 10 µM for Semax, and found that pentapeptide fragments inhibited too while tri-, tetra- and hexapeptide fragments did not (reference 7). In mice, a 100 µg/kg dose of Selank was reported to increase the half-life of plasma leu-enkephalin in BALB/c mice and to produce an open-field effect, while C57Bl/6 mice showed neither (reference 3). That concordance between enzyme data and behavior within one strain is what supports the enkephalinase hypothesis, though it remains a correlation.

GABAergic gene expression and receptor binding

In rat frontal cortex, a study measured 84 neurotransmission-related genes by real-time PCR after Selank or GABA at 300 µg/kg and reported significant changes in 45 genes at 1 hour and 22 genes at 3 hours, with a positive correlation between the Selank and GABA changes (reference 8). A radioligand study reported that Selank affected [3H]GABA binding as a positive allosteric modulator and that its joint action with some benzodiazepines was not simply additive (reference 9). A cell-culture study in IMR-32 neuroblastoma cells reported no change in the studied genes with Selank alone, although combinations with GABA or olanzapine did change expression patterns (reference 10). The difference between the in vivo and in vitro results is itself informative: the effect may depend on the tissue context.

Electrophysiology and neurotrophin expression

Application of Selank at 1–8 µM to rat hippocampal slices increased the amplitude and discharge rate of spontaneous inhibitory postsynaptic currents in CA1 pyramidal neurons, without clear dose dependence in that range (reference 11). A separate study reported that Selank prevented an ethanol-related rise in BDNF content in hippocampus and frontal cortex in rats (reference 12). These findings are consistent with a GABA-related interpretation, but each comes from a defined preparation and is not a proof of mechanism.

Designing a clean behavioral experiment

The published abstracts imply several design choices that a laboratory can adopt without any further assumptions about the compound.

  • Pick strains deliberately. Include a higher-anxiety and a lower-anxiety strain if the question is about the compound rather than the animal. Record supplier, age, sex and housing.
  • Match the vehicle. The control group receives the identical diluent, same volume and same route, on the same schedule. Preservatives such as benzyl alcohol in a bacteriostatic diluent are part of the vehicle and belong in the methods.
  • Blind the scorer. Open-arm entries are countable by software; withdrawal indices and rearing are partly judgment calls.
  • Use a positive control. The morphine-withdrawal study compared Selank with diazepam, which is how its effect size was framed (reference 2).
  • Randomize test order and time of day. Corticosterone and activity follow circadian rhythms.
  • Pre-specify the primary readout. Choose one (for example open-arm time fraction) before unblinding, and regard the rest as exploratory.

Material identity matters as much as behavior. The product page names Selank as C33H57N11O9 with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, and the COA page is where lot-level HPLC data appear where published. File the lot record with the experiment. Selank purity testing and understanding HPLC purity explain what the figure means, including why chromatographic purity is not the same as peptide content.

Stock preparation arithmetic for behavioral cohorts

Concentration is the vial mass divided by the diluent volume: C (mg/mL) = m (mg) ÷ V (mL). A study that specifies a dose per kilogram of body weight in its own protocol converts it into a working concentration through the same relationship: required mass per animal = (reported amount per kg) × (animal mass in kg), and stock volume per animal = required mass ÷ C. Publications report amounts of this kind in micrograms per kilogram; the numbers in a paper describe what that paper used, not a recommendation. Run the arithmetic in the reconstitution calculator, write each figure in the notebook, and prepare enough stock for the entire cohort so that every animal receives material from one preparation.

Selank has no tryptophan, methionine or cysteine residues, so oxidation and disulfide chemistry are not the main stability risks. The practical risks are peptidase contamination, adsorption to plastic at low concentration, and microbial growth in a stock entered many times. How to reconstitute a lyophilized peptide and storing research peptides cover the handling steps, and the product page gives storage at 2–8 °C with −20 °C for long-term holding, protected from heat, moisture and light.

General peptide-stability work provides the vocabulary for the remaining risks: aggregation, chemical degradation and the stress of freezing are reviewed in the pharmaceutical literature (reference 13). Selank's proline-rich sequence makes it a short, hydrophilic peptide, so aggregation is less likely than for a lipidated analog, but a frozen stock should still be divided into single-use portions.

Reading the evidence: strengths and limits

Claim in the literatureType of evidenceHow to word it
Inhibits enkephalin-degrading enzymesIn vitro enzyme assays with human serum and mouse plasma"Inhibited enkephalin hydrolysis in vitro with IC50 values in the micromolar range"
Alters GABAergic gene expressionqPCR panels in rat cortex; null result in neuroblastoma cells"Changed expression of many neurotransmission genes in vivo; not in IMR-32 cells alone"
Acts as positive allosteric modulator of GABA bindingRadioligand binding on membranes"Enhanced [3H]GABA binding in a membrane preparation"
Reduces behavioral signs of anxietyStrain-dependent rodent paradigms"Altered exploration in BALB/c but not C57BL/6 mice"
Modulates cytokine and immune-gene expressionSpleen qPCR, serum cytokines under stress"Changed expression of 34 inflammation-related genes in mouse spleen at 6 and 24 hours" (reference 14)

Several limits apply across the board. Many of the primary papers come from a small number of laboratories, several appear in regional journals, and independent replication is thinner than for classical anxiolytic pharmacology. Doses and routes differ from paper to paper. A convenient summary is that Selank has an interesting, internally coherent set of preclinical observations that justify further controlled work and do not justify broad statements. The tuftsin parent has its own receptor biology: tuftsin has been reported to bind neuropilin-1 and signal through the TGF-beta pathway in microglia (reference 15), but whether Selank shares that route is not established by the abstracts cited here, so this article makes no such claim.

For comparison with its sister peptide, Selank versus Semax sets the two side by side. For practical sourcing questions see where to buy Selank, and the shop lists all research vials.

Documentation checklist for a Selank behavioral study

  1. Compound: lot number, supplied form, storage history and the COA reference where available.
  2. Vehicle: diluent type, preservative, volume, pH if measured.
  3. Stock: mass, volume, calculated concentration, date and time of preparation, storage tier.
  4. Animals: species, strain, sex, age, housing, light cycle, acclimation period.
  5. Apparatus: maze dimensions, illumination in lux, cleaning between animals.
  6. Scoring: software or observer, blinding, primary and secondary outcomes fixed in advance.
  7. Exclusions: criteria written before the experiment, with the number of animals excluded and why.

That list is generic good practice; none of it is specific to this compound, which is the point. The compound's literature is mostly a story about conditions, and the record is what lets another laboratory reproduce them. All material discussed here is for laboratory research use only.

Frequently asked questions

What does anxiolytic mean in Selank research?

It is an operational label: in rodent paradigms such as the open field and elevated plus-maze, animals given Selank showed more exploration or fewer defensive behaviors than controls in some strains. It does not identify a receptor and it is not a statement about any use outside the laboratory.

Which rodent models have been used with Selank?

Published abstracts describe open-field testing in BALB/c and C57Bl/6 mice, elevated plus-maze testing in the same strains, naloxone-precipitated morphine withdrawal scoring in rats, hippocampal slice electrophysiology and stress paradigms with cytokine readouts.

Why does mouse strain matter so much?

In the cited mouse work, effects appeared in BALB/c mice, which have lower baseline exploration and higher anxiety, and not in C57BL/6 mice. A study confined to the wrong strain can record a null result that says nothing about the compound.

Is a single receptor responsible for Selank's reported effects?

No single receptor is established. Reports describe enkephalin-degrading enzyme inhibition, effects on GABAergic gene expression, positive allosteric modulation of GABA binding in membranes and immune-gene changes.

Did Selank change GABA-related genes in cell culture?

In IMR-32 neuroblastoma cells, Selank alone did not change the measured mRNA levels, although combinations with GABA or olanzapine changed expression patterns. In rat frontal cortex, many genes changed. The difference points to tissue context.

How strong is the evidence base?

It is a coherent set of preclinical observations, mostly from a small number of laboratories, with differing doses and routes and limited independent replication. Wording in a manuscript should describe the model and the readout, not a general effect.

What concentration math applies to a stock vial?

Concentration in mg/mL equals vial mass in mg divided by diluent volume in mL. Per-animal mass is the reported amount per kilogram multiplied by body mass in kilograms. The calculator on the site performs the arithmetic; the protocol decides the numbers.

How should lyophilized Selank be stored?

The product page states refrigeration at 2–8 °C, −20 °C for long-term holding, and protection from heat, moisture and light. Reconstituted stock should be kept cold, labeled with the lot and concentration, and divided into single-use portions if frozen.

Where can the lot analytical data be found?

Certificates of analysis are listed on the COA page where published. File the lot number and any HPLC figure with the experiment record.

Does this article cover use outside the laboratory?

No. Selank is supplied for laboratory research use only, and the article describes published preclinical studies and bench handling.

Related reading: Selank Nasal Spray Research: Intranasal Studies Explained, Selank Research Peptide: What the Evidence Shows, Selank and Semax Stack Research: Combination Design.

References

  1. Pellow S, Chopin P, File SE, Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods. 1985;14(3):149-67. doi:10.1016/0165-0270(85)90031-7
  2. Konstantinopolsky MA, Chernyakova IV, Kolik LG. Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats. Bull Exp Biol Med. 2022;173(6):730-733. doi:10.1007/s10517-022-05624-x
  3. Sokolov OY, Meshavkin VK, Kost NV, Zozulya AA. Effects of Selank on behavioral reactions and activities of plasma enkephalin-degrading enzymes in mice with different phenotypes of emotional and stress reactions. Bull Exp Biol Med. 2002;133(2):133-5. doi:10.1023/a:1015582302311
  4. Vasil'eva EV, Kondrakhin EA, Salimov RM, Kovalev GI. [COMPARISON OF PHARMACOLOGICAL EFFECTS OF HEPTAPEPTIDE SELANK AFTER INTRANASAL AND INTRAPERITONEAL ADMINISTRATION TO BALB/c AND C57BL/6 MICE.]. Eksp Klin Farmakol. 2016;79(9):3-11. PMID: 29787664
  5. Leonidovna YA, Aleksandrovna SM, Aleksandrovna TA, Aleksandrovna BO, Fedorovich MN, Aleksandrovna AL. The Influence of Selank on the Level of Cytokines Under the Conditions of "Social" Stress. Curr Rev Clin Exp Pharmacol. 2021;16(2):162-167. doi:10.2174/1574884715666200704152810
  6. Zozulya AA, Kost NV, Yu Sokolov O, Gabaeva MV, Grivennikov IA, Andreeva LN, et al. The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. Bull Exp Biol Med. 2001;131(4):315-7. doi:10.1023/a:1017979514274
  7. Kost NV, Sokolov OIu, Gabaeva MV, Grivennikov IA, Andreeva LA, Miasoedov NF, et al. [Semax and selank inhibit the enkephalin-degrading enzymes from human serum]]. Bioorg Khim. 2001;27(3):180-3. PMID: 11443939
  8. Volkova A, Shadrina M, Kolomin T, Andreeva L, Limborska S, Myasoedov N, et al. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Front Pharmacol. 2016;7:31. doi:10.3389/fphar.2016.00031
  9. Vyunova TV, Andreeva L, Shevchenko K, Myasoedov N. Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein Pept Lett. 2018;25(10):914-923. doi:10.2174/0929866525666180925144642
  10. Filatova E, Kasian A, Kolomin T, Rybalkina E, Alieva A, Andreeva L, et al. GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells. Front Pharmacol. 2017;8:89. doi:10.3389/fphar.2017.00089
  11. Povarov IS, Kondratenko RV, Derevyagin VI, Myasoedov NF, Skrebitsky VG. Effect of Selank on Spontaneous Synaptic Activity of Rat Hippocampal CA1 Neurons. Bull Exp Biol Med. 2017;162(5):640-642. doi:10.1007/s10517-017-3676-3
  12. Kolik LG, Nadorova AV, Antipova TA, Kruglov SV, Kudrin VS, Durnev AD. Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats. Bull Exp Biol Med. 2019;167(5):641-644. doi:10.1007/s10517-019-04588-9
  13. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544-75. doi:10.1007/s11095-009-0045-6
  14. Kolomin T, Shadrina M, Andreeva L, Slominsky P, Limborska S, Myasoedov N. Expression of inflammation-related genes in mouse spleen under tuftsin analog Selank. Regul Pept. 2011;170(1-3):18-23. doi:10.1016/j.regpep.2011.05.001
  15. Nissen JC, Selwood DL, Tsirka SE. Tuftsin signals through its receptor neuropilin-1 via the transforming growth factor beta pathway. J Neurochem. 2013;127(3):394-402. doi:10.1111/jnc.12404

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.